Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
PTX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume766.17K
Average Volume (3M)690.15K
Market Cap
AU$54.68M
Enterprise ValueAU$45.41M
Total Cash (Recent Filing)AU$9.77M
Total Debt (Recent Filing)AU$495.89K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetMinimal debt reduces refinancing and interest‑rate risk and preserves financial flexibility. For a cash‑consuming biotech this conservatism lengthens runway, lowers mandatory financing costs and supports continued R&D spend and strategic optionality over the coming months.
Strong Revenue GrowthOrganic revenue rising ~44% YoY signals expanding uptake of the company’s programs or non‑dilutive funding progress. Durable top‑line growth improves operating leverage potential, helping scale development costs and increasing the probability of reaching sustainable profitability over a multi‑quarter horizon.
Consistently High Gross ProfitPersistently high gross profit implies favorable unit economics for core products/programs. Strong underlying margins mean incremental revenue contributes meaningfully to covering fixed R&D and SG&A, supporting margin sustainability as the business scales over the medium term.
Bears Say
Structural Operating LossesPersistent operating losses indicate the company cannot self‑fund its development and commercialization activities. Continued negative earnings pressures equity, forces repeated external raises, increases dilution risk and constrains the firm’s ability to invest for growth without external capital.
Consistent Negative Operating And Free Cash FlowNegative OCF and FCF each year, with FCF deteriorating in 2025, signal rising cash burn and weakening internal liquidity. This elevates dependency on capital markets, shortens funding runway between financings, and raises the likelihood of dilutive capital raises or constrained program timelines.
Erosion Of Capital Base And Negative ROEDeclining equity and assets alongside negative ROE show shareholder capital is being consumed by ongoing losses. Over time this reduces the company’s internal investment capacity, weakens the balance sheet buffer for setbacks, and increases reliance on external funding under potentially adverse terms.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$54.68M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 150 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.353%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
-62.49%
Trailing 12-Months
Asset Growth
11.46%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Starpharma Holdings Limited
―
Avecho Biotechnology Limited
―
Chimeric Therapeutics Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---